Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shot up 1.4% during trading on Friday . The stock traded as high as $7.71 and last traded at $7.48, with a volume of 61,796 shares trading hands. The stock had previously closed at $7.38.

Several brokerages have recently issued reports on ADAP. Leerink Swann reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “sell” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Adaptimmune Therapeutics PLC – presently has an average rating of “Buy” and an average target price of $15.94.

The company’s market capitalization is $538.67 million. The firm has a 50-day moving average price of $8.18 and a 200 day moving average price of $8.63.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last posted its earnings results on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. On average, equities research analysts predict that Adaptimmune Therapeutics PLC – will post ($1.16) earnings per share for the current year.

In related news, Director Orbimed Advisors Llc purchased 1,712,400 shares of the business’s stock in a transaction on Tuesday, May 24th. The stock was acquired at an average price of $10.42 per share, with a total value of $17,843,208.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Charles Elliott Sigal purchased 45,000 shares of the business’s stock in a transaction on Wednesday, May 18th. The stock was bought at an average cost of $1.53 per share, with a total value of $68,850.00. Following the purchase, the director now owns 52,938 shares in the company, valued at $80,995.14. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Adaptimmune Therapeutics PLC – stock. Jennison Associates LLC increased its position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 486,948 shares of the company’s stock after buying an additional 1,547 shares during the period. Jennison Associates LLC owned about 0.69% of Adaptimmune Therapeutics PLC – worth $5,873,000 as of its most recent filing with the SEC.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.